BioCentury | May 30, 2020
Tools & Techniques

Denali offers rare peek into the science behind its CNS delivery platform

Denali is lifting the veil on the delivery technology it’s using to transport large molecules into the CNS, detailing a differentiated strategy for hijacking the transferrin receptor. The company revealed features of its large molecule...
BioCentury | Feb 28, 2020
Deals

Biogen expands its modality toolkit in Alzheimer’s and Parkinson’s with Sangamo deal

In its latest CNS partnership, Biogen is doubling down on targets already in its pipeline with a gene regulation technology from Sangamo it hopes will shut down target expression altogether. By closing off target expression,...
BC Extra | Jan 15, 2020
Clinical News

Denali gains on Parkinson’s results as it looks to select a Phase II candidate

Denali reported data Tuesday from pair of Phase I trials that will inform the company’s selection of a Parkinson’s disease candidate to advance to Phase II. Denali Therapeutics Inc. (NASDAQ:DNLI) gained $5.16 (29%) to $22.74...
BC Extra | Dec 6, 2019
Preclinical News

Dec. 5 Preclinical Quick Takes: Simpler synthesis of Merck’s HIV therapy; plus MRSA antibiotic, once-monthly oral contraceptive

Merck, Codexis design efficient synthesis of Phase II HIV therapy  Merck & Co. Inc. (NYSE:MRK) and Codexis Inc. (NASDAQ:CDXS) researchers designed a way to synthesize HIV therapy islatravir (MK-8591) via a three-step biocatalytic cascade in...
BC Extra | Sep 12, 2019
Preclinical News

Sept. 12 Preclinical Quick Takes: Stephen Quake newco reveals epigenomic platform; plus Personal Genome, Summit and Biolife4D

Bluestar’s epigenomic platform IDs breast, pancreatic cancer  Bluestar Genomics Inc. (San Francisco, Calif.) showed it correctly identified breast and pancreatic cancers with areas under the curve of 0.89 and 0.95, respectively, with its machine learning...
BC Extra | May 8, 2019
Preclinical News

May 8 Preclinical Quick Takes: Moderna, WntRx, schizophrenia, heart attack

Moderna debuts candidate for rare glycogen storage disease  Moderna Inc. (NASDAQ:MRNA) revealed a new preclinical mRNA candidate to treat glycogen storage disease type Ia -- mRNA-3745, which encodes G6PC. The company presented data at the...
BC Innovations | Apr 25, 2019
Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for their...
BC Week In Review | Feb 15, 2019
Clinical News

Sangamo looks to next-gen therapies after reporting first version 'not enough'

Sangamo Therapeutics Inc. (NASDAQ:SGMO) reported interim data from two Phase I/II trials evaluating its in vivo genome editing zinc finger nuclease (ZFN) therapies SB-913 to treat mucopolysaccharidosis II (MPS II, Hunter syndrome) and SB-318 to...
BC Extra | Feb 8, 2019
Clinical News

Sangamo looks to next-gen therapies after reporting first version 'not enough'

Sangamo Therapeutics Inc. (NASDAQ:SGMO) lost $3.71 (31%) to $8.31 Thursday after the company reported interim data from two Phase I/II trials evaluating its in vivo genome editing zinc finger nuclease (ZFN) therapies SB-913 to treat...
BC Week In Review | Jan 11, 2019
Company News

Canbridge, Green Cross in China deal for MPS II therapy

In the latest deal between Chinese and Korean biopharmas, Canbridge Pharmaceuticals Inc. (Beijing, China) gained exclusive rights in Greater China to commercialize Hunterase (GC1111) from Green Cross Corp. (KSE:006280) to treat mucopolysaccharidosis II (MPS II,...
Items per page:
1 - 10 of 58